79351833 - BICYCLE THERAPEUTICS

Information

• Trademark
• 79351833

• Source

• Serial Number

  79351833

• Registration Number

  7178565

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  November 26, 2021
  2 years ago

• Registration Date

  October 03, 2023
  8 months ago

• Transaction Date

  January 30, 2024
  4 months ago

• Status Date

  October 03, 2023
  8 months ago

• Published for Opposition Date

  July 18, 2023
  10 months ago

• Location Date

  October 03, 2023
  8 months ago

• Status Code

  700

• Current Location

  PUBLICATION AND ISSUE SECTION

  Employee Name

  ORNDORFF, LINDA B

• Attorney Docket Number

  580952

  Attorney Name

  Andrew D. Price

  Law Office Assigned Location Code

  M20

• Owners

  • BicycleTx Limited

Case File Statements

• DM0000: The mark consists of the wording BICYCLE in black with the two letters "C" stylized in gold over the word THERAPEUTICS in black.
• GS0051: Pharmaceuticals, namely, preparations and products for use in the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for use in the treatment and prevention of metabolic disease, urology and renal disease, in the cardiovascular field, in the field of hematology, for use in the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevetion of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging, namely, clinical imaging agents; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease
• CC0000: The color(s) black and gold is/are claimed as a feature of the mark.
• GS0441: Medical services; healthcare services for the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for the treatment and prevention of metabolic disease, urology and renal disease, cardiovascular diseases, for the treatment and prevention of disease in the field of hematology, for the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals; medical and pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in the field of respiratory disease; medical services in the field of cardiovascular disease; medical services in the field of metabolic disease; medical services in the field of the treatment and/or prevention of viral infections; medical services in the field of diagnostics and imaging; medical services in the field of renal disease; medical services in the field of gastrointestinal disease; medical services in the field of muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in the field of respiratory disease; pharmaceutical compounding services in the field of cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid; medical testing for diagnostic or treatment purposes in the field of oncology for both solid and liquid tumours, metabolic disease, urology and renal disease, cardiovascular diseases, hematology, respiratory disease, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders
• D10000: "THERAPEUTICS"
• GS0421: Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and medical and scientific research, namely, conducting clinical trials for others; medical and scientific research, namely, conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid

Case File Event Statements

• 1/30/2024 - 4 months ago

  27 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO

• 1/9/2024 - 5 months ago

  26 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS

• 1/9/2024 - 5 months ago

  25 - FINAL DISPOSITION PROCESSED Type: FIMP

• 1/3/2024 - 5 months ago

  24 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR

• 12/16/2023 - 5 months ago

  23 - CHANGE OF NAME/ADDRESS REC'D FROM IB Type: ADCH

• 12/1/2023 - 6 months ago

  22 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP

• 10/3/2023 - 8 months ago

  21 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC

• 10/3/2023 - 8 months ago

  20 - REGISTERED-PRINCIPAL REGISTER Type: R.PR

• 7/18/2023 - 10 months ago

  19 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 7/18/2023 - 10 months ago

  18 - PUBLISHED FOR OPPOSITION Type: PUBO

• 6/28/2023 - 11 months ago

  17 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 6/13/2023 - 12 months ago

  16 - EXAMINERS AMENDMENT MAILED Type: CNEA

• 6/13/2023 - 12 months ago

  15 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 6/13/2023 - 12 months ago

  14 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 6/13/2023 - 12 months ago

  13 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 6/12/2023 - 12 months ago

  12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 6/12/2023 - 12 months ago

  11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 6/12/2023 - 12 months ago

  10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 1/15/2023 - a year ago

  9 - REFUSAL PROCESSED BY IB Type: RFNP

• 12/23/2022 - a year ago

  8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS

• 12/22/2022 - a year ago

  7 - REFUSAL PROCESSED BY MPU Type: RFRR

• 10/11/2022 - a year ago

  6 - APPLICATION FILING RECEIPT MAILED Type: MAFR

• 10/8/2022 - a year ago

  5 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR

• 10/7/2022 - a year ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 10/7/2022 - a year ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 10/7/2022 - a year ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 10/6/2022 - a year ago

  1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR